Betapace_AF

Category

Betapace_AF




Useful info

Betapace_AF Brand names, Betapace_AF Analogs

Betapace_AF Brand Names Mixture

  • No information avaliable
  • Betapace_AF Chemical_Formula

    C11H87Al9O55S8

    Betapace_AF RX_link

    http://www.rxlist.com/cgi/generic/sucral.htm

    Betapace_AF fda sheet

    Betapace_AF msds (material safety sheet)

    Betapace_AF MSDS

    Betapace_AF Synthesis Reference

    No information avaliable

    Betapace_AF Molecular Weight

    1599.14 g/mol

    Betapace_AF Melting Point

    No information avaliable

    Betapace_AF H2O Solubility

    Insoluble in cold water

    Betapace_AF State

    Solid

    Betapace_AF LogP

    No information avaliable

    Betapace_AF Dosage Forms

    Suspension; Tablet for oral administration (1g)

    Betapace_AF Indication

    For the short-term treatment (up to 8 weeks) of active duodenal ulcer. Also used as maintenance therapy for duodenal ulcer patients at reduced dosage (1 gram twice a day) after healing of acute ulcers.

    Betapace_AF Pharmacology

    Sucralfate is a prescription medication used to treat peptic ulcers. The current clinical uses of sucralfate are limited. It is effective for the healing of duodenal ulcers, but it is not frequently used for this since more effective drugs (e.g. proton pump inhibitors) have been developed. Although the mechanism of sucralfate's ability to accelerate healing of duodenal ulcers remains to be fully defined, it is known that it exerts its effect through a local, rather than systemic, action. Chemically, sucralfate is a complex of the disaccharide sugar, sucrose, combined with sulfate and aluminum. In acidic solutions (e.g. gastric acid) it forms a thick paste that has a strong negative charge.

    Betapace_AF Absorption

    Minimally absorbed from the gastrointestinal tract (up to 5% of the disaccharide component and less than 0.02% of aluminum).

    Betapace_AF Toxicity

    Acute oral toxicity (LD50) in mice is >8000 mg/kg. There is limited experience in humans with overdosage of sucralfate. Sucralfate is only minimally absorbed from the gastrointestinal tract and thus risks associated with acute overdosage should be minimal. In rare reports describing sucralfate overdose, most patients remained asymptomatic.

    Betapace_AF Patient Information

    Betapace_AF Organisms Affected

    Humans and other mammals